Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

NCT02584075 on ClinicalTrials.gov · last registry update 2015-10-22

100 participants. Its estimated completion date, November 2017, has passed with no update to the record. Primary outcome, as filed: Coronary endothelial function. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here.

Status: UNKNOWN
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: Beijing Chao Yang Hospital
Sponsor type: Other
Enrollment: 100
Started: 2015-11
Primary completion: 2017-11 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Coronary endothelial function

Conditions studied

Coronary Endothelial Function

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.